nevirapine has been researched along with abacavir in 98 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (8.16) | 18.2507 |
| 2000's | 46 (46.94) | 29.6817 |
| 2010's | 40 (40.82) | 24.3611 |
| 2020's | 4 (4.08) | 2.80 |
| Authors | Studies |
|---|---|
| Haefeli, WE; Ketabi-Kiyanvash, N; Lindenmaier, H; Theile, D; Weiss, J | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Bachmann, MH; Fessel, WJ; Kagan, RM; Mitsuya, Y; Shafer, RW; Shahriar, R; Varghese, V | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Danner, SA; de Wolf, F; Goudsmit, J; Hoetelmans, RM; Jurriaans, S; Lange, JM; Lukashov, VV; Notermans, DW; Prins, JM; Roos, M; Schuitemaker, H; Weverling, GJ | 1 |
| Saag, MS; Schooley, RT | 1 |
| Everall, IP; Gonzalez, A | 1 |
| Becker, M; Chesney, M; Deeks, SG; Grant, RM; Hellmann, NS; Parkin, NT; Petropoulos, CJ; Symonds, W; Volberding, PA | 1 |
| Crowe, S | 1 |
| Temesgen, Z; Wright, AJ | 1 |
| Bernasconi, E; Carota, A; Magenta, L; Moccetti, T; Piffaretti, JC | 1 |
| Balzarini, J; Burt, V; Carbonez, A; De Clercq, E; Kleim, JP | 1 |
| Burger, DM; Hoetelmans, RM; Jurriaans, S; Lange, JM; Portegies, P; Prins, JM; Sommadossi, JP; Turner-Foisy, ML; van Praag, RM; Weverling, GJ; Zhou, XJ | 1 |
| Cheesbrough, A; Gazzard, BG; Leen, C; Moyle, GJ; Reynolds, B; Wilkins, E | 1 |
| Baldwin, C; Moyle, G | 1 |
| Gerstoft, J; Jørgensen, LB; Katzenstein, TL; Mathiesen, LR; Nielsen, C; Pedersen, C | 1 |
| Carr, A; Chuah, J; Cooper, DA; Doong, N; French, M; Hoy, J; Hudson, J; Law, M; Mallal, S; Smith, D | 1 |
| Nelson, M | 1 |
| Beniowski, M; Carlier, H; de Vries, C; Gray, G; Horban, A; Lafeuillade, A; Lange, JM; Lazzarin, A; Paes, D; Schmidt, RE; van Leeuwen, R; van Weert, L; Wit, FW; Wood, R | 1 |
| de Groot, R; Fraaij, PL; van Rossum, AM | 1 |
| de Wolf, F; Jurriaans, S; Lange, JM; Prins, JM; van Praag, RM; Wit, FW | 1 |
| Almond, LM; Back, DJ; De Vries, C; Gould, J; Hoggard, PG; Kewn, S; Khoo, SH; Lou, Y; Maherbe, A; Sales, SD; Wood, R | 1 |
| Everall, IP; Foster, R; Olajide, D | 1 |
| Adorni, F; Bini, T; Bongiovanni, M; Capetti, A; Castelnuovo, B; Chiesa, E; Cicconi, P; d'Arminio Monforte, A; Faggion, I; Melzi, S; Mussini, C; Rizzardini, G; Rusconi, S; Sollima, S; Tordato, F | 1 |
| Aranda, M; Arnaiz, JA; Cortés, C; Cruceta, A; Dalmau, D; de Lazzari, E; Domingo, P; Force, L; Gatell, JM; Javaloyas, M; Knobel, H; Llibre, JM; Martínez, E; Pedrol, E; Podzamczer, D; Ribera, E; Richart, C; Riera, M; Segura, F | 1 |
| Gerstoft, J; Katzenstein, TL; Kirk, O; Lundgren, JD; Mathiesen, L; Nielsen, H; Obel, N; Pedersen, C | 1 |
| Bossi, P; Bricaire, F; Caumes, E; Katlama, C | 1 |
| Leen, CL | 1 |
| Danner, SA; Gruzdev, B; Jurriaans, S; Lange, JM; Peeters, M; Prins, JM; Rakhmanova, A; Sankatsing, SU; van't Klooster, G; Weverling, GJ | 1 |
| Boyle, BA | 1 |
| Chiesi, A; Fisher, M; Horban, A; Kirk, O; Ledergerber, B; Lundgren, JD; Machala, L; Mulchany, F; Phillips, AN; Reiss, P | 1 |
| Gerber, JG; Wyles, DL | 1 |
| García-Gibert, L; Giménez-Arnau, AM; Knobel, H; Montero, M | 1 |
| Crespo, M; Ferrer, E; Fisac, C; Fumero, E; Gatell, JM; Podzamczer, D; Ribera, E; Roson, B; Virgili, N | 1 |
| Bonjoch, A; Clotet, B; De la Torre, J; Galvez, J; Martínez, E; Miralles, C; Miranda, J; Muñoz-Moreno, JA; Paredes, R; Prieto, A; Videla, S; Vilades, C | 1 |
| Arnedo, M; Dalmau, D; Domingo, P; Gatell, JM; González, A; Llibre, JM; Martinez, E; Ochoa de Echagüen, A; Ribera, E; Riera, M; Rosón, B; Xercavins, M | 1 |
| Billaud, E; Bugnon, F; Cua, E; Cuzin, L; Dellamonica, P; Delpierre, C; Massip, P; Pugliese, P; Raffi, F | 1 |
| Almeida, CA; Mallal, S; Martin, A; Nolan, D; Rauch, A | 1 |
| Abgrall, S; Bouchaud, O; Costagliola, D; Yeni, PG | 2 |
| Arnaiz, JA; Dalmau, D; de Lazzari, E; Domingo, P; Force, L; Gatell, JM; Knobel, H; Leyes, M; Martínez, E; Pedrol, E; Podzamczer, D; Ribera, E | 1 |
| Anastos, K; Cohen, M; Cole, S; Hessol, NA; Justman, J; Kaplan, RC; Lu, D; Shi, Q; Tien, PC; Vigen, C; Young, M | 1 |
| Alonzi, T; Ascenzi, P; Mancone, C; Narciso, P; Notari, S; Tripodi, M | 1 |
| Gatanaga, H; Honda, H; Oka, S | 1 |
| Bruynzeel, DP; Milpied, B; Phillips, EJ; Shear, NH | 1 |
| Roca, B | 1 |
| Berzins, B; Evans, S; Forand, J; Hafner, R; Murphy, R; Owens, S; Shevitz, A; Tashima, K; Tebas, P; Yarasheski, K; Zhang, J | 1 |
| Fisac, C; Gatell, JM; Martínez, E; Podzamczer, D; Ribera, E; Virgili, N | 1 |
| Ackermans, MT; Arenas-Pinto, A; Brinkman, K; Franssen, R; Hassink, E; Hutten, B; Kastelein, JJ; Oesterholt, R; Reiss, P; Sankatsing, RR; Sauerwein, HP; Storfer, SP; Stroes, ES | 1 |
| Nageswara Rao, R; Shinde, DD | 1 |
| Tozzi, V | 1 |
| Burke, A; Dunn, DT; Gibb, DM; Gilks, CF; Goodall, RL; Kaleebu, P; Katundu, P; Kityo, C; Lyagoba, F; McCormick, A; Munderi, P; Ndembi, N; Pillay, D; Robertson, V; Walker, AS; Yirrell, DL | 1 |
| Asahchop, EL; Brenner, BG; Moisi, D; Ntemgwa, M; Toni, TA; Wainberg, MA | 1 |
| Abaine, D; Aber, M; Ahimbisibwe, F; Akao, J; Akuma, S; Amuron, B; Amurwon, J; Angweng, E; Anywar, W; Atwiine, D; Atwiine, S; Awio, P; Babiker, A; Babiker, AG; Bafana, T; Bagaya, L; Bahendeka, S; Bakeinyaga, GT; Barungi, G; Bassett, M; Bohannon, J; Boocock, K; Borok, M; Bray, D; Breckenridge, A; Bulaya-Tembo, R; Buluma, E; Burke, A; Burke, C; Byakwaga, H; Byamukama, A; Byaruhanga, R; Chakonza, L; Chidziva, E; Chigwedere, E; Chimanzi, J; Chimbetete, C; Chirairo, H; Chirara, M; Chirema, O; Chitsungo, S; Chivhunga, T; Coutinho, A; Darbyshire, JH; Drasiku, A; Dunn, D; Enzama, R; Etukoit, B; Fadhiru, K; Ferrier, A; Florence, A; Foster, S; Gazzard, B; Generous, L; Gibb, DM; Gilks, C; Gilks, CF; Goodall, R; Grosskurth, H; Grundy, C; Haguma, W; Hakim, J; Hill, C; Hughes, P; Jamu, A; Jangano, M; Jones, S; Kabanda, J; Kabuye, G; Kagina, G; Kajungu, D; Kaleebu, P; Kambungu, A; Kankunda, R; Karungi, J; Kasirye, R; Katabira, E; Katabira, H; Katundu, P; Khauka, P; Kigozi, J; Kikaire, B; Kityo, C; Komugyena, J; Kulume, R; Kusiima, A; Kyomugisha, H; Labeja, O; Lara, AM; Latif, A; Levin, J; Lubwama, E; Lutwama, F; Lyagoba, F; Machingura, I; Machingura, J; Makota, S; Mambule, I; Mapinge, F; Mapuchere, C; Massa, R; Matenga, J; Matongo, M; Maweni, C; Mawora, A; McCormick, A; McLaren, A; Mdege, N; Moyo, K; Muchabaiwa, L; Mudzingwa, S; Mufuka-Kapuya, C; Muganzi, A; Mugisha, A; Mugurungi, O; Mugyenyi, P; Muhweezi, D; Muhwezi, A; Mukiibi, S; Mukose, A; Mulindwa, G; Mulindwa, M; Munderi, P; Murungi, S; Musana, H; Musoro, G; Mutowo, J; Mutsai, S; Muvirimi, C; Muyingo, S; Muzambi, M; Mwebesa, D; Mwesigwa, P; Nabankema, E; Nabongo, P; Naidoo, B; Nairuba, R; Nakahima, W; Nakazibwe, M; Nakiyingi, J; Nalumenya, R; Namale, L; Namara, W; Namata, I; Namazzi, A; Namuli, T; Namyalo, M; Nanfuka, A; Nanfuka, R; Nassuna, G; Ndembi, N; Newland, C; Ngorima, N; Nimwesiga, E; Nsibambi, D; Nyachwo, L; Nyiraguhirwa, D; Ochai, R; Ojiambo, H; Ojiambo, W; Oketta, F; Omony, W; Otim, T; Oyugi, J; Palfreeman, A; Pascoe, M; Pearce, G; Peto, L; Peto, T; Phiri, M; Pillay, D; Pozniak, A; Puddephatt, C; Rahim, S; Rauchenberger, M; Reid, A; Robertson, V; Ronald, A; Rooney, J; Ruberantwari, A; Rutikarayo, N; Sabiiti, J; Sadik, F; Sematala, F; Serwadda, D; Sheehan, S; Simango, M; Smith, M; Snowden, W; Spencer-Drake, C; Spyer, M; Ssali, F; Steens, JM; Svovanapasis, P; Takubwa, J; Taylor, K; Taziwa, F; Tinago, G; Todd, J; Tugume, S; Tukamushaba, J; Tumukunde, D; Tumusiime, C; Twijukye, C; Vere, L; Waita, R; Wakholi, BN; Walker, AS; Walusimbi, J; Wangati, K; Wanyama, J; Wapakhabulo, AC; Warambwa, C; Warara, R; Wavamunno, P; Weller, I; Whitworth, J; Wilkes, H; Winogron, D; Yirrell, D; Zalwango, A; Zalwango, E; Zawedde, C; Zengeza, E | 1 |
| Battegay, M; Bernasconi, E; Cavassini, M; Elzi, L; Furrer, H; Hirschel, B; Ledergerber, B; Marzolini, C; Vernazza, P; Weber, R | 1 |
| Babiker, AG; Darbyshire, JH; Gibb, DM; Gilks, CF; Grosskurth, H; Kityo, C; Mugyenyi, P; Munderi, P; Reid, A; Ssali, F; Walker, AS | 1 |
| Butini, L; Cirioni, O; Costantini, A; Giacometti, A; Montroni, M; Scalise, G | 1 |
| Gilks, CF; Hughes, AR; Kabuye, G; Kityo, C; Mosteller, M; Munderi, P; Snowden, WB; Ssali, F; Thoofer, NK; Walker, AS | 1 |
| Domingo, P; Gutierrez, Mdel M; Mateo, MG; Vidal, F | 1 |
| Abgrall, S; Bommenel, T; Costagliola, D; Gilquin, J; Katlama, C; Lascaux, AS; Launay, O; Mahamat, A; Martinez, V; Meynard, JL; Pradier, C; Rouveix, E; Simon, A | 1 |
| Bacheler, L; Dunn, DT; Gilks, C; Goodall, RL; Kaleebu, P; Kityo, C; Munderi, P; Pillay, D; Ranopa, M; Van Houtte, M | 1 |
| Gibb, DM; Gilks, CF; Grosskurth, H; Hakim, J; Kityo, C; Mambule, I; Munderi, P; Reid, A; Ssali, F; Stöhr, W; Walker, AS | 1 |
| Côté, HC; Hukezalie, KR; Thumati, NR; Wong, JM | 1 |
| Capparelli, E; Essex, M; Leidner, J; Lockman, S; Makhema, J; Moffat, C; Moss, M; Moyo, S; Ogwu, A; Rossi, S; Shapiro, RL | 1 |
| Bayonne Kombo, ES; Gathse, A | 1 |
| Bosco, O; Cruciani, M; Malena, M; Mengoli, C; Parisi, SG; Serpelloni, G | 1 |
| Achan, J; Ades, V; Aliba Luwedde, F; Clark, T; Cohan, D; Havlir, D; Kakuru, A; Kamya, M; Mwesigwa, J; Natureeba, P; Osterbauer, B; Plenty, A | 1 |
| Gilks, CF; Goodall, RL; Gupta, RK; Kaleebu, P; Kityo, C; Lyagoba, F; Mugarura, L; Munderi, P; Pillay, D; Ranopa, M | 1 |
| Karlin, E; Phillips, E | 1 |
| Dunn, DT; Gibb, DM; Gilks, CF; Goodall, RL; Kaleebu, P; Kasirye, R; Kityo, C; Mambule, I; Mugyenyi, P; Pillay, D; Walker, AS | 1 |
| Abongomera, G; Arach, B; Asiimwe, AR; Cook, A; Gibb, DM; Kabamba, D; Kayiwa, J; Kekitiinwa, A; Kenny, J; Kityo, C; Klein, N; Komunyena, J; Mirembe, G; Mulenga, V; Musiime, V; Nansubuga, C; Walker, SA; Wavamunno, P; Zangata, D | 1 |
| Mushiroda, T | 1 |
| Borroni, RG | 1 |
| Boettiger, DC; Chaiwarith, R; Choi, JY; Ditangco, R; Kamarulzaman, A; Kantipong, P; Kerr, S; Kiertiburanakul, S; Kumarasamy, N; Law, M; Lee, C; Li, CK; Merati, TP; Mustafa, M; Ng, OT; Oka, S; Pham, TT; Pujari, S; Ratanasuwan, W; Sohn, A; Van Kinh, N; Vonthanak, S; Wong, WW; Yunihastuti, E; Zhang, F | 1 |
| Abongomera, G; Asiimwe, A; Burger, D; Chabala, C; Chintu, C; Cook, AD; Gibb, DM; Kekitiinwa, A; Kenny, J; Kityo, C; Klein, N; McIlleron, H; Mirembe, G; Mulenga, V; Musiime, V; Owen-Powell, E; Thomason, MJ; Walker, AS | 1 |
| Bani-Sadr, F; Cabie, A; Cotte, L; de Boissieu, P; Delobel, P; Dramé, M; Garraffo, R; Huleux, T; Poizot-Martin, I; Raffi, F; Rey, D | 1 |
| Abach, J; Abongomera, G; Chabala, C; Colebunders, R; Cook, A; Gibb, DM; Kekitiinwa, A; Kityo, C; Lamorde, M; Mulenga, V; Musiime, V; Thomason, M; Walker, AS | 1 |
| Dunn, DT; Gilks, C; Goodall, RL; Gupta, RK; Kaleebu, P; Kityo, C; Mugarura, L; Munderi, P; Nkurunziza, P; Pattery, T; Pillay, D | 1 |
| Fricke-Galindo, I; LLerena, A; López-López, M | 1 |
| Chareonyingwattana, A; Prasertvit, P; Wattanakrai, P | 1 |
| Emanuel, K; Fox, HS; Lamberty, BG; Morsey, B; Stauch, KL | 1 |
| Chimukangara, B; Katzenstein, D; Manasa, J; Masimirembwa, C; Mitchell, R; Nyabadza, G | 1 |
| Awodele, O; Oshikoya, KA; Popoola, TD | 1 |
| Chiesi, S; Lanzafame, M; Lattuada, E; Piacentini, D; Rizzardo, S; Vento, S | 1 |
| Akakpo, AS; Bassowa, A; Dapam, AN; Kombaté, K; Laouali, AY; Mahamadou, G; Mensah, E; Mouhari-Toure, A; Pitché, P; Saka, B; Teclessou, JN | 1 |
| Brigante, G; Casarini, L; Diazzi, C; Guaraldi, G; Lania, AG; Lazzaretti, C; Potì, F; Prodam, F; Riccetti, L; Rochira, V; Rofrano, L; Sperduti, S | 1 |
| Chen, SQ; Cui, YM; Hu, K; Ma, LY; Mu, GY; Wang, Z; Xiang, Q; Xie, QF; Zhang, XD; Zhang, Z; Zhou, S | 1 |
| Bonora, S; Calcagno, A; De Benedetto, I; Guastamacchia, G; Trunfio, M | 1 |
| Kunene, PN; Mahlambi, PN | 1 |
| Mahlambi, P; Ngwenya, N | 1 |
23 review(s) available for nevirapine and abacavir
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Antiretroviral chemotherapy.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Ritonavir; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 1998 |
New reverse transcriptase inhibitors.
Topics: Adenine; Alkynes; Benzoxazines; Cyclopropanes; Delavirdine; Dideoxynucleosides; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Nevirapine; Organophosphonates; Oxazines; Prodrugs; Reverse Transcriptase Inhibitors; Soman; Uracil | 1999 |
Antiretrovirals.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; Female; Furans; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Pregnancy; Pregnancy Complications, Infectious; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Stavudine; Sulfonamides; Zalcitabine; Zidovudine | 1999 |
The role of NNRTIs in antiretroviral combination therapy: an introduction.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; HIV Infections; Humans; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors | 2001 |
Efficacy of highly active antiretroviral therapy in HIV-1 infected children.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Indinavir; Nelfinavir; Nevirapine; Oxazines; Ritonavir; Saquinavir | 2002 |
Antiretroviral therapy-induced psychosis: case report and brief review of the literature.
Topics: Adult; Antipsychotic Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Combinations; Female; Hallucinations; HIV Seropositivity; Humans; Lamivudine; Nevirapine; Psychoses, Substance-Induced; Zidovudine | 2003 |
[Antiretroviral-induced toxiderma in HIV-infected patients].
Topics: Alkynes; Anti-HIV Agents; Anti-Inflammatory Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Hypersensitivity; Exanthema; Histamine H1 Antagonists; HIV Infections; HIV Protease Inhibitors; Humans; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Risk Factors; Steroids; Stevens-Johnson Syndrome | 2003 |
Perspectives on HAART: switch maintenance therapy.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; HIV Infections; HIV Protease Inhibitors; Humans; Lipodystrophy; Metabolic Diseases; Nevirapine; Oxazines; Patient Compliance; Reverse Transcriptase Inhibitors | 2003 |
The continuing evolution of HIV therapy.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Cyclopropanes; Delayed-Action Preparations; Deoxycytidine; Didanosine; Dideoxynucleosides; Drug Monitoring; Emtricitabine; Furans; HIV Infections; Humans; Lamivudine; Nevirapine; Oligopeptides; Organophosphates; Organophosphonates; Organophosphorus Compounds; Oxazines; Pyridines; Randomized Controlled Trials as Topic; Stavudine; Sulfonamides; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2003 |
Predicting and diagnosing abacavir and nevirapine drug hypersensitivity: from bedside to bench and back again.
Topics: Animals; Anti-HIV Agents; Biomarkers; Dideoxynucleosides; Drug Hypersensitivity; HIV-1; Humans; Nevirapine | 2006 |
Pharmacogenetic information derived from analysis of HLA alleles.
Topics: Alleles; Animals; Anti-HIV Agents; Dideoxynucleosides; Drug Hypersensitivity; HLA Antigens; Humans; Nevirapine; Pharmacogenetics | 2008 |
A review of drug patch testing and implications for HIV clinicians.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Hypersensitivity; HIV Infections; Humans; Nevirapine; Patch Tests | 2008 |
Pharmacogenomics of antiretrovirals.
Topics: Alkynes; Anti-Retroviral Agents; Aryl Hydrocarbon Hydroxylases; Atazanavir Sulfate; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; Cytochrome P-450 CYP2B6; Dideoxynucleosides; Drug Hypersensitivity; Drug Resistance, Viral; Dyslipidemias; Genetic Predisposition to Disease; Genetic Testing; Glucuronosyltransferase; HLA Antigens; Humans; Hyperbilirubinemia; Nevirapine; Oligopeptides; Oxidoreductases, N-Demethylating; Patents as Topic; Patient Selection; Pharmacogenetics; Pyridines; Ritonavir | 2008 |
Pharmacogenetics of antiretrovirals.
Topics: Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Dideoxynucleosides; Glucuronosyltransferase; HIV Infections; HLA-A Antigens; HLA-B Antigens; HLA-DRB1 Chains; Humans; Nevirapine; Oligopeptides; Oxidoreductases, N-Demethylating; Pharmacogenetics; Pyridines | 2010 |
The toxicogenetics of antiretroviral therapy: the evil inside.
Topics: Alkynes; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Hypersensitivity; Genetic Variation; Humans; Nevirapine; Oligopeptides; Polymorphism, Single Nucleotide; Pyridines; Reverse Transcriptase Inhibitors; Toxicogenetics | 2011 |
Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Drug Substitution; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lipids; Maintenance Chemotherapy; Middle Aged; Nevirapine; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Treatment Failure; Viral Load; Young Adult; Zidovudine | 2013 |
Genotyping for severe drug hypersensitivity.
Topics: Allopurinol; Amoxicillin-Potassium Clavulanate Combination; Carbamazepine; Dideoxynucleosides; Drug Hypersensitivity; Genotype; HLA-B Antigens; Humans; Nevirapine; Pharmacogenetics; Protein Conformation; Stevens-Johnson Syndrome | 2014 |
[Future direction of pharmacogenomics: identification of genes associated with risk of adverse drug reactions using genome-wide association study].
Topics: Anticonvulsants; Carbamazepine; Dideoxynucleosides; Drug Eruptions; Genetic Predisposition to Disease; Genome-Wide Association Study; Genotyping Techniques; HLA Antigens; Humans; Intracellular Signaling Peptides and Proteins; Nevirapine; Pharmacogenetics; Polymorphism, Genetic; Risk | 2014 |
Pharmacogenetic markers of severe cutaneous adverse drug reactions.
Topics: Allopurinol; Anti-HIV Agents; Anticonvulsants; Biomarkers; Carbamazepine; Dideoxynucleosides; Drug Eruptions; Drug Hypersensitivity Syndrome; Enzyme Inhibitors; Genes, MHC Class I; Genome-Wide Association Study; Genotype; HLA Antigens; Humans; Nevirapine; Pharmacogenetics; Polymorphism, Single Nucleotide; Stevens-Johnson Syndrome | 2014 |
An update on HLA alleles associated with adverse drug reactions.
Topics: Alleles; Allopurinol; Carbamazepine; Dideoxynucleosides; Drug-Related Side Effects and Adverse Reactions; Economics, Pharmaceutical; HLA Antigens; Humans; Nevirapine | 2017 |
Associations between human leukocyte antigen polymorphisms and hypersensitivity to antiretroviral therapy in patients with human immunodeficiency virus: a meta-analysis.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Hypersensitivity; Female; HIV Infections; HLA Antigens; Humans; Male; Nevirapine; Odds Ratio; Polymorphism, Single Nucleotide | 2019 |
A review of the potential mechanisms of neuronal toxicity associated with antiretroviral drugs.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Astrocytes; Atazanavir Sulfate; Benzoxazines; Central Nervous System; Cognitive Dysfunction; Cyclopropanes; Dideoxynucleosides; Endothelial Cells; HIV Infections; Humans; Neurons; Nevirapine; Nitriles; Oligodendroglia; Pyrimidines | 2020 |
27 trial(s) available for nevirapine and abacavir
| Article | Year |
|---|---|
Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome.
Topics: Adult; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Male; Nelfinavir; Nevirapine; Phenotype; Prospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Salvage Therapy; Saquinavir | 1999 |
HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Composition; Carnitine; Dideoxynucleosides; Drug Administration Schedule; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hydroxyurea; Insulin Resistance; Lipodystrophy; Male; Middle Aged; Nevirapine; Organophosphonates; Quality of Life; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome | 2001 |
Prednisolone does not prevent hypersensitivity reactions in antiretroviral drug regimens containing abacavir with or without nevirapine.
Topics: Adult; Anti-HIV Agents; Anti-Inflammatory Agents; Dideoxynucleosides; Drug Hypersensitivity; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nevirapine; Prednisolone; Reverse Transcriptase Inhibitors | 2001 |
Time-dependent changes in HIV nucleoside analogue phosphorylation and the effect of hydroxyurea.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Interactions; Drug Resistance, Viral; Female; HIV Infections; Humans; Hydroxyurea; Lamivudine; Leukocytes, Mononuclear; Male; Middle Aged; Nevirapine; Nucleosides; Phosphorylation; Reverse Transcriptase Inhibitors; Zidovudine | 2002 |
Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection.
Topics: Adult; Aged; Alkynes; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Disease Progression; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Failure | 2003 |
Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Lactates; Male; Middle Aged; Nelfinavir; Nervous System Diseases; Nevirapine; Ritonavir; RNA, Viral; Saquinavir; Stavudine; Treatment Outcome | 2003 |
TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Zidovudine | 2003 |
Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine.
Topics: Adult; Alkynes; Anthropometry; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Blood Glucose; Cholesterol; Cholesterol, HDL; Cyclopropanes; Dideoxynucleosides; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Insulin Resistance; Lipodystrophy; Male; Middle Aged; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Triglycerides | 2005 |
Antiretroviral treatment simplification with 3 NRTIs or 2 NRTIs plus nevirapine in HIV-1-infected patients treated with successful first-line HAART.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Nevirapine; Patient Compliance; Patient Satisfaction; Prospective Studies; Quality of Life; Reverse Transcriptase Inhibitors; RNA, Viral; Zidovudine | 2005 |
Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with nevirapine, efavirenz or abacavir.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Resistance, Viral; Follow-Up Studies; Genotype; HIV Infections; HIV-1; Humans; Middle Aged; Mutation; Nevirapine; Oxazines; Phenotype; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Failure | 2005 |
Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Disease Progression; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Nevirapine; Reverse Transcriptase Inhibitors; Treatment Outcome | 2007 |
Twenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA).
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Dideoxynucleosides; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Reverse Transcriptase Inhibitors; Treatment Outcome; Uganda; Zidovudine | 2008 |
Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Intra-Abdominal Fat; Lopinavir; Male; Middle Aged; Nevirapine; Pyrimidinones; Radiography, Abdominal; Stavudine; Thigh; Viral Load; Zidovudine | 2009 |
Nevirapine increases high-density lipoprotein cholesterol concentration by stimulation of apolipoprotein A-I production.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Apolipoprotein A-I; Cholesterol, HDL; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Kinetics; London; Magnetic Resonance Spectroscopy; Male; Middle Aged; Netherlands; Nevirapine; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Up-Regulation; Viral Load | 2009 |
Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus Abacavir.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Mutation; Nevirapine; RNA, Viral; Uganda; Viral Load; Zidovudine | 2010 |
Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Africa; Aged; Anemia; Anti-Retroviral Agents; CD4 Lymphocyte Count; Creatinine; Dideoxynucleosides; Disease Progression; Drug Monitoring; Female; Glomerular Filtration Rate; Hemoglobins; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Male; Middle Aged; Neutropenia; Neutrophils; Nevirapine; Organophosphonates; RNA, Viral; Tenofovir; Urea; Viral Load; Zidovudine | 2010 |
Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.
Topics: Adult; Body Weight; CD4 Lymphocyte Count; Dideoxynucleosides; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Medication Adherence; Middle Aged; Nevirapine; Recurrence; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Uganda; Viral Load; Zidovudine | 2010 |
Distribution of HLA-B alleles in a Ugandan HIV-infected adult population: NORA pharmacogenetic substudy of DART.
Topics: Adult; Anti-HIV Agents; Dideoxynucleosides; Double-Blind Method; Drug Hypersensitivity; Gene Frequency; Genetic Predisposition to Disease; Genotype; HIV Infections; HLA-B Antigens; Humans; Nevirapine; Uganda | 2011 |
Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; Dideoxynucleosides; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nevirapine; Prospective Studies; Treatment Outcome; Viral Load | 2011 |
Residual activity of two HIV antiretroviral regimens prescribed without virological monitoring.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Lamivudine; Nevirapine; RNA, Viral; Viral Load; Zidovudine | 2011 |
Glomerular dysfunction and associated risk factors over 4-5 years following antiretroviral therapy initiation in Africa.
Topics: Adenine; Adult; Africa; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Creatinine; Dideoxynucleosides; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases; Kidney Glomerulus; Lamivudine; Male; Nevirapine; Organophosphonates; Risk Factors; Tenofovir; Time Factors; Zidovudine | 2011 |
Therapeutic levels of lopinavir in late pregnancy and abacavir passage into breast milk in the Mma Bana Study, Botswana.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Botswana; Breast Feeding; Dideoxynucleosides; Female; HIV Infections; HIV-1; Humans; Infant; Lactation; Lamivudine; Lopinavir; Middle Aged; Milk, Human; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Viral Load; Zidovudine | 2013 |
WHO option B+: early experience of antiretroviral therapy sequencing after cessation of breastfeeding and risk of dermatologic toxicity.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Breast Feeding; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Dideoxynucleosides; Drug Eruptions; Drug Substitution; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lopinavir; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Protease Inhibitors; Ritonavir; Uganda; World Health Organization | 2013 |
High rate of HIV resuppression after viral failure on first-line antiretroviral therapy in the absence of switch to second-line therapy.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Humans; Lamivudine; Nevirapine; Viral Load; Viremia; Zidovudine | 2014 |
High level of viral suppression and low switch rate to second-line antiretroviral therapy among HIV-infected adult patients followed over five years: retrospective analysis of the DART trial.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cross-Sectional Studies; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Probability; Retrospective Studies; RNA, Viral; Tenofovir; Uganda; Viral Load; Zidovudine | 2014 |
Anthropometric measurements and lipid profiles to detect early lipodystrophy in antiretroviral therapy experienced HIV-infected children in the CHAPAS-3 trial.
Topics: Anthropometry; Anti-HIV Agents; Child; Child, Preschool; Cross-Sectional Studies; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lipid Metabolism; Lipodystrophy; Lipoproteins, HDL; Lipoproteins, LDL; Male; Nevirapine; Stavudine; Triglycerides; Viral Load; Zidovudine | 2014 |
Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant; Lamivudine; Male; Nevirapine; Stavudine; Tablets; Uganda; Zambia; Zidovudine | 2016 |
48 other study(ies) available for nevirapine and abacavir
| Article | Year |
|---|---|
Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors.
Topics: Animals; Anti-HIV Agents; Cell Line; Dogs; Humans; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Reverse Transcriptase Inhibitors | 2007 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility.
Topics: Amino Acid Sequence; Anti-HIV Agents; Drug Resistance, Viral; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Nucleosides; Phenotype; Reverse Transcriptase Inhibitors | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy.
Topics: Adult; Anti-HIV Agents; Data Interpretation, Statistical; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Virus Replication; Zidovudine | 1998 |
Lest we forget: neuropsychiatry and the new generation anti-HIV drugs.
Topics: Anti-HIV Agents; Antipsychotic Agents; Blood-Brain Barrier; Central Nervous System; Cytochrome P-450 Enzyme System; Dementia; Dideoxynucleosides; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Mental Disorders; Nevirapine; Reverse Transcriptase Inhibitors | 1998 |
Are nelfinavir-containing regimens effective as second-line triple therapy?
Topics: Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Nelfinavir; Nevirapine; Retrospective Studies; Reverse Transcriptase Inhibitors; Stavudine | 2000 |
Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors.
Topics: Alkynes; Anilides; Anti-HIV Agents; Benzoxazines; Cell Line; Cyclopropanes; Delavirdine; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Combinations; Drug Resistance, Microbial; Furans; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Microbial Sensitivity Tests; Mutation; Nevirapine; Oxazines; Quinoxalines; Reverse Transcriptase Inhibitors; Thioamides; Uracil | 2000 |
Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir.
Topics: Adult; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Disease Reservoirs; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Middle Aged; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Semen; Stavudine; Viral Load; Zidovudine | 2000 |
Salvage therapy with abacavir plus efavirenz or nevirapine in HIV-1-infected persons with previous nucleoside analogue and protease inhibitor use.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Nevirapine; Oxazines; Retrospective Studies; Reverse Transcriptase Inhibitors; Salvage Therapy | 2000 |
Switching from a PI-based to a PI-sparing regimen for management of metabolic or clinical fat redistribution.
Topics: Acquired Immunodeficiency Syndrome; Adipose Tissue; Alkynes; Benzoxazines; Cyclopropanes; Dideoxynucleosides; HIV Protease Inhibitors; Humans; Lipodystrophy; Nevirapine; Oxazines | 2000 |
Genotypic and phenotypic nevirapine resistance correlates with virological failure during salvage therapy including abacavir and nevirapine.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; DNA, Viral; Drug Resistance, Microbial; Drug Therapy, Combination; Genotype; HIV Infections; HIV-1; Humans; Molecular Sequence Data; Nevirapine; Phenotype; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Salvage Therapy; Viral Load | 2000 |
Salvage therapy studies.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir; Nevirapine; Reverse Transcriptase Inhibitors; Salvage Therapy; Saquinavir; Viral Load | 1998 |
Antivirals update.
Topics: Anti-HIV Agents; Carbamates; Delavirdine; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Drugs, Investigational; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nevirapine; Reverse Transcriptase Inhibitors; Salvage Therapy; Sulfonamides | 1998 |
Improved long-term suppression of HIV-1 replication with a triple-class multidrug regimen compared with standard of care antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Follow-Up Studies; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Middle Aged; Nevirapine; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors; Viral Load; Virus Replication; Zidovudine | 2002 |
Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Nevirapine; Oxazines; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome | 2003 |
Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; Dideoxynucleosides; Female; HIV Infections; Humans; Male; Nelfinavir; Nevirapine; Oxazines; Prospective Studies; Viral Load | 2004 |
Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Hepatitis; HIV Infections; Humans; Indinavir; Liver Function Tests; Lopinavir; Nelfinavir; Nevirapine; Oxazines; Protease Inhibitors; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Zidovudine | 2005 |
[Toxic epidermal necrolysis associated with abacavir].
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Didanosine; Dideoxynucleosides; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Male; Nevirapine; Reverse Transcriptase Inhibitors; Stavudine; Stevens-Johnson Syndrome | 2005 |
Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Dideoxynucleosides; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Oxazines; Prospective Studies; Reverse Transcriptase Inhibitors; Treatment Failure; Treatment Outcome; Viral Load; Zidovudine | 2005 |
Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Nevirapine; Oxazines; Prospective Studies; Reverse Transcriptase Inhibitors; Risk Factors; Treatment Outcome; Viral Load | 2006 |
Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing efavirenz, nevirapine, or abacavir.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Nevirapine; Oxazines; Protease Inhibitors; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load; Virus Replication | 2007 |
Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Black People; Cholesterol; Cross-Sectional Studies; Cyclopropanes; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Fasting; Female; Hispanic or Latino; HIV Infections; HIV Protease Inhibitors; HIV Seronegativity; HIV Seropositivity; HIV-1; Humans; Indinavir; Lamivudine; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Multivariate Analysis; Nelfinavir; Nevirapine; Organophosphonates; Ritonavir; Stavudine; Tenofovir; Triglycerides; United States; White People | 2007 |
Determination of abacavir, amprenavir, didanosine, efavirenz, nevirapine, and stavudine concentration in human plasma by MALDI-TOF/TOF.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Carbamates; Cyclopropanes; Didanosine; Dideoxynucleosides; Drug Monitoring; Feasibility Studies; Furans; Humans; Molecular Structure; Nevirapine; Reverse Transcriptase Inhibitors; Sensitivity and Specificity; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Spectrophotometry, Ultraviolet; Stavudine; Sulfonamides | 2008 |
Proinflammatory cytokine changes in clinically stable, virologically suppressed, HIV-infected patients switching from protease inhibitors to abacavir.
Topics: Adiponectin; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Administration Schedule; HIV Infections; Humans; Nevirapine; Receptors, Tumor Necrosis Factor, Type II | 2009 |
Two-dimensional LC-MS/MS determination of antiretroviral drugs in rat serum and urine.
Topics: Animals; Anti-Retroviral Agents; Calibration; Chromatography, Liquid; Dideoxynucleosides; Drug Monitoring; Equipment Design; Models, Chemical; Nevirapine; Rats; Rats, Wistar; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Time Factors | 2009 |
Development of an allele-specific PCR for detection of the K65R resistance mutation in patients infected with subtype C human immunodeficiency virus type 1.
Topics: Alkynes; Alleles; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Nevirapine; Polymerase Chain Reaction; Zidovudine | 2010 |
Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Nevirapine; Oligopeptides; Organophosphonates; Proportional Hazards Models; Prospective Studies; Pyridines; Pyrimidinones; Risk Factors; Switzerland; Tenofovir; Zidovudine | 2010 |
[Durability and tolerability of long-term nevirapine-based HAART].
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Comorbidity; Dideoxynucleosides; Female; Hepatitis, Viral, Human; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lipids; Liver Function Tests; Male; Middle Aged; Nevirapine; Retrospective Studies; Stavudine; Viral Load; Young Adult; Zidovudine | 2010 |
In vitro and ex vivo inhibition of human telomerase by anti-HIV nucleoside reverse transcriptase inhibitors (NRTIs) but not by non-NRTIs.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cell Line; Cyclopropanes; Didanosine; Dideoxynucleosides; DNA Primers; Dose-Response Relationship, Drug; Humans; In Vitro Techniques; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Stavudine; Telomerase; Tenofovir; Zidovudine | 2012 |
[Tenofovir hypersensitivity to tenofovir (DRESS) syndrome in a female patient infected by HIV].
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Asthenia; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Eruptions; Drug Hypersensitivity; Drug Substitution; Emtricitabine; Female; Fever; HIV Infections; Humans; Lamivudine; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Syndrome; Tenofovir | 2013 |
Trends in first-line antiretroviral therapy in Asia: results from the TREAT Asia HIV observational database.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Asia; Dideoxynucleosides; Drug-Related Side Effects and Adverse Reactions; Female; HIV; HIV Infections; Humans; Male; Nevirapine; Reverse Transcriptase Inhibitors; Stavudine | 2014 |
Long-term efficacy and toxicity of abacavir/lamivudine/nevirapine compared to the most prescribed ARV regimens before 2013 in a French Nationwide Cohort Study.
Topics: Adult; Dideoxynucleosides; Drug Therapy, Combination; Female; France; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Prospective Studies; Reverse Transcriptase Inhibitors; Treatment Outcome | 2016 |
Improved Adherence to Antiretroviral Therapy Observed Among HIV-Infected Children Whose Caregivers had Positive Beliefs in Medicine in Sub-Saharan Africa.
Topics: Africa South of the Sahara; Alkynes; Anti-HIV Agents; Attitude to Health; Benzoxazines; Caregivers; Child; Child, Preschool; Cyclopropanes; Dideoxynucleosides; Female; HIV Infections; Humans; Infant; Lamivudine; Linear Models; Logistic Models; Male; Medication Adherence; Multivariate Analysis; Nevirapine; Randomized Controlled Trials as Topic; Stavudine; Surveys and Questionnaires; Uganda; Zambia; Zidovudine | 2017 |
Rapid accumulation of HIV-1 thymidine analogue mutations and phenotypic impact following prolonged viral failure on zidovudine-based first-line ART in sub-Saharan Africa.
Topics: Adult; Africa South of the Sahara; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Nevirapine; Polymerase Chain Reaction; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Thymidine; Treatment Failure; Viral Load; Zidovudine | 2017 |
Nevirapine patch testing in Thai human immunodeficiency virus infected patients with nevirapine drug hypersensitivity.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Hypersensitivity; HIV; Humans; Nevirapine; Patch Tests; Predictive Value of Tests; Thailand | 2017 |
Central nervous system-penetrating antiretrovirals impair energetic reserve in striatal nerve terminals.
Topics: Adenosine Triphosphate; Alkynes; Animals; Anti-HIV Agents; Benzoxazines; Cerebral Cortex; Corpus Striatum; Cyclohexanes; Cyclopropanes; Darunavir; Dideoxynucleosides; Dose-Response Relationship, Drug; Emtricitabine; Lopinavir; Male; Maraviroc; Mitochondria; Neurons; Nevirapine; Oxidative Phosphorylation; Permeability; Presynaptic Terminals; Raltegravir Potassium; Rats; Rats, Long-Evans; Triazoles; Zidovudine | 2017 |
Community Based Antiretroviral Treatment in Rural Zimbabwe.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Child; Child, Preschool; Community Health Centers; Cross-Sectional Studies; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; Female; HIV-1; Humans; Lopinavir; Male; Middle Aged; Nevirapine; Ritonavir; Rural Population; Treatment Failure; Viral Load; Young Adult; Zimbabwe | 2017 |
A prospective study of adverse events to antiretroviral therapy in HIV- infected adults in Ekiti State, Nigeria.
Topics: Abdominal Pain; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Substitution; Drug Therapy, Combination; Female; HIV Infections; Humans; Incidence; Lamivudine; Male; Middle Aged; Nausea; Nevirapine; Nigeria; Prospective Studies; Sleep Initiation and Maintenance Disorders; Tenofovir; Young Adult; Zidovudine | 2016 |
"High" antiretroviral deintensification, a strategy to avoid drug interactions and unfavourable long-term effects of HAART.
Topics: Adult; Aged; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Interactions; HIV Infections; Humans; Male; Middle Aged; Nevirapine | 2018 |
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)-induced Stevens-Johnson syndrome and gynecomastia in an HIV-infected child: A case report.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Substitution; Gynecomastia; HIV Infections; Humans; Lamivudine; Male; Mucositis; Nevirapine; Reverse Transcriptase Inhibitors; Stevens-Johnson Syndrome | 2018 |
Abacavir, nevirapine, and ritonavir modulate intracellular calcium levels without affecting GHRH-mediated growth hormone secretion in somatotropic cells in vitro.
Topics: Anti-Retroviral Agents; Calcium; Cell Line; Cell Survival; Cyclic AMP; Cyclic AMP Response Element-Binding Protein; Dideoxynucleosides; Growth Hormone-Releasing Hormone; Human Growth Hormone; Humans; Nevirapine; Phosphorylation; Ritonavir; Somatotrophs; Transfection | 2019 |
Case study on antiretroviral drugs uptake from soil irrigated with contaminated water: Bio-accumulation and bio-translocation to roots, stem, leaves, and fruits.
Topics: Bioaccumulation; Fruit; HIV Infections; Humans; Nevirapine; Soil; Soil Pollutants; Vegetables; Water; Water Pollution | 2023 |
Methods optimization and application: Solid phase extraction, ultrasonic extraction and Soxhlet extraction for the determination of antiretroviral drugs in river water, wastewater, sludge, soil and sediment.
Topics: Ecosystem; HIV Infections; Humans; Nevirapine; Rivers; Sewage; Soil; Solid Phase Extraction; Ultrasonics; Wastewater; Water; Water Pollutants, Chemical | 2023 |